GlobeNewswire🇺🇸 US
Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
- Priority Review granted; PDUFA target action date set for January 21, 2027 -
News/Dyne Therapeutics Announces U.S. FDA Acceptance …